Trinity Biotech (TRIB) Q4 2025 earnings summary

Executive summary

• Like-for-like revenue for Q4 2025 was $11.0m, down from $15.1m in Q4 2024, mainly due to lower HIV sales and supply chain adjustments for TrinScreen demand.

• Net loss for Q4 2025 was $17.5m (Q4 2024: $17.0m), impacted by a one-off $10.0m IFRS charge related to financing modifications.

• For FY2025, like-for-like revenue was $43.3m, down from $58.8m in 2024, with net loss at $37.4m (2024: $31.8m).

• Adjusted EBITDA improved to negative $0.5m in Q4 2025 (Q4 2024: negative $7.0m) and negative $5.9m for FY2025 (2024: negative $11.3m), reflecting transformation-driven profitability improvements.

Financial highlights

• Q4 2025 total revenue: $11.1m (Q4 2024: $15.9m); FY2025 total revenue: $43.8m (2024: $61.6m).

• Q4 2025 gross margin: 35.2% (Q4 2024: 30.8%); FY2025 gross margin: 38.6% (2024: 34.8%).

• Q4 2025 gross profit: $3.9m (Q4 2024: $4.9m); FY2025 gross profit: $16.9m (2024: $21.4m).

• Basic and diluted loss per ADS for Q4 2025: $0.9 (Q4 2024: $1.3); FY2025: $2.0 (2024: $1.8).

Outlook and guidance

• Revenue and profitability improvements are expected as transformation initiatives continue and manufacturing transitions stabilize.